PRAVIGARD PAC (COPACKAGED)
LOE ApproachingNDAORALTABLET
Approved
Jun 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRAVIGARD PAC is a copackaged oral tablet combination product approved by Bristol Myers Squibb in 2003. The specific indications and mechanism of action are not publicly detailed in available data. This product represents a fixed-dose combination strategy typical of cardiovascular or metabolic disease management.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting declining team investment and potential restructuring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring; careers on this product are in wind-down or defensive mode. Professionals should expect limited growth opportunities and consider transition planning as LOE approaches.
Brand ManagerCommercial Operations Analyst
Worked on PRAVIGARD PAC (COPACKAGED) at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.